Skip to main content

Table 2 Chemotherapy regimens received

From: Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?

  N %
First-line 83 100
 - FOLFIRINOX 42 50.6
 - nabPGem 41 49.4
 - Death after 1st-line or not 16 19.3
 - suitable for 2nd-line   
 - too early (1st-line ongoing) 3 3.6
Second-line 64 100
 - FOLFIRINOX 13 20.3
 - nabPGem 35 54.7
 - Nal-IRI 11 17.2
 - FOLFOX 2 3.1
 - FOLFIRI 2 3.1
 - Gem/Erlotinib 1 1.6
 - Death after 2nd-line or not suitable for 3rd-line 19 29.7
 - too early (2nd-line ongoing) 10 15.6
Third-line 35 100
 - FOLFIRINOX re-induction 8 22.9
 - nabPGem 6 17.1
 - FOLFOX 2 5.7
 - Gem/Erlotinib 11 31.4
 - nab-Pacl/5-FU 1 2.9
 - nal-IRI 5 14.3
 - FOLFIRI 3 8.6
 - nal-IRI/Erlotinib 2 5.7
> Fourth-line 17